The company said the Board appointed William G. Kaelin Jr., M.D. to the Board on November 5, 2025 and determined that he satisfies the New York Stock Exchange definition of an independent director.

1. 01

   The company said the Board appointed William G. Kaelin Jr., M.D. to the Board on November 5, 2025 and determined that he satisfies the New York Stock Exchange definition of an independent director.

2. 02

   The company said Dr. Kaelin is expected to enter into the Company's standard indemnification agreement with non-management directors and will participate in the non-employee director compensation arrangements established by the Company for non-employee directors, as described in the Company's proxy statement dated February 28, 2025.

3. 03

   The company said in a press release that Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women's Hospital and was awarded the Nobel Prize in Physiology or Medicine in 2019. It also said he serves as chair of the Science and Technology Committee on the board of directors of Eli Lilly and Company.

4. 04

   The company said Dr. Kaelin holds a Doctor of Medicine from Duke University School of Medicine, is the author of hundreds of peer-reviewed publications and holds multiple patents related to cancer biology and hypoxia signaling.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.